Moderna (MRNA) Tops Q2 EPS by 42c
Get Alerts MRNA Hot Sheet
Join SI Premium – FREE
Moderna (NASDAQ: MRNA) reported Q2 EPS of $6.46, $0.42 better than the analyst estimate of $6.04. Revenue for the quarter came in at $4.35 billion versus the consensus estimate of $4.28 billion.
- Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose
For earnings history and earnings-related data on Moderna (MRNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Arca Biopharma (ABIO) Reports Q1 Loss of $0.14
- Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!